| 11.1 -1.5 (-11.9%) | 03-26 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.42 |
1-year : | 26.65 |
| Resists | First : | 18.34 |
Second : | 22.82 |
| Pivot price | 14.54 |
|||
| Supports | First : | 11.1 |
Second : | 9.23 |
| MAs | MA(5) : | 12.6 |
MA(20) : | 14.26 |
| MA(100) : | 14.56 |
MA(250) : | 20.18 |
|
| MACD | MACD : | -0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 7.6 |
D(3) : | 11.5 |
| RSI | RSI(14): 41 |
|||
| 52-week | High : | 35.16 | Low : | 10.9 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AGE ] has closed above bottom band by 18.2%. Bollinger Bands are 137.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 12.6 - 12.71 | 12.71 - 12.78 |
| Low: | 10.91 - 11.01 | 11.01 - 11.08 |
| Close: | 10.97 - 11.12 | 11.12 - 11.23 |
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.
Fri, 22 Mar 2024
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results - Yahoo Finance
Wed, 30 Aug 2023
Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement - Business Wire
Tue, 23 May 2023
AgeX Therapeutics Announces Appeal of NYSE American Determination - Business Wire
Wed, 22 Mar 2023
Juvenescence Now Owns 78.70% of AgeX Therapeutics (AGE) - Nasdaq
Wed, 15 Dec 2021
AgeX Therapeutics’ Licensee ImStem Biotechnology Does First U.S. Multiple Sclerosis Patient with IMS001 - BioInformant
Fri, 23 Jul 2021
AgeX Therapeutics and LyGenesis Terminate Merger Negotiations - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 1.844e+007 (%) |
| Held by Institutions | 43.4 (%) |
| Shares Short | 92 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.05e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 516.4 % |
| Return on Equity (ttm) | -72 % |
| Qtrly Rev. Growth | 94000 % |
| Gross Profit (p.s.) | 435.4 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -22.51 |
| Dividend | 0 |
| Forward Dividend | 41220 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|